Kumar S, et al. (2017) Sirtuin1-regulated lysine acetylation of p66Shc governs diabetes-induced vascular oxidative stress and endothelial dysfunction. Proc Natl Acad Sci U S A 114, 1714-1719 28137876

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S36-p - SHC1 (mouse) ▲

Modsite: TPPEELPsPSASSLG SwissProt Entrez-Gene Orthologous residues SHC1 (human): S36‑p, SHC1 iso2 (human): ‑, SHC1 iso3 (human): ‑, SHC1 iso6 (human): S36‑p, SHC1 iso7 (human): ‑, SHC1 (mouse): S36‑p, SHC1 iso2 (mouse): ‑, SHC1 iso3 (mouse): ‑, SHC1 (rat): S36‑p, SHC1 iso2 (rat): ‑ Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial), endothelial-aorta, HUVEC (endothelial) Cellular systems studied:  cell lines, tissue Species studied:  human, mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes SIRT1 (human) no change compared to control SIRT1 KD increases nicotinamide increase high_glucose increase

K81-ac - SHC1 (mouse) ▲

Modsite: AGGRLGPkGEPGKAA SwissProt Entrez-Gene Orthologous residues SHC1 (human): K81‑ac, SHC1 iso2 (human): ‑, SHC1 iso3 (human): ‑, SHC1 iso6 (human): K81‑ac, SHC1 iso7 (human): ‑, SHC1 (mouse): K81‑ac, SHC1 iso2 (mouse): ‑, SHC1 iso3 (mouse): ‑, SHC1 (rat): K81‑ac, SHC1 iso2 (rat): ‑ Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro), modification-specific antibody, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial), endothelial-aorta, HUVEC (endothelial) Cellular systems studied:  cell lines, tissue Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme DEACETYLASE SIRT1 (human) ACETYLTRANSFERASE p300 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes DEACETYLASE SIRT1 (human) co-immunoprecipitation, genetic knockout/knockin of upstream enzyme, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme ACETYLTRANSFERASE p300 (human) transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA increase SIRT1 siRNA nicotinamide increase streptozotocin increase high_glucose increase Downstream Regulation Effect of modification (function):  intracellular localization, phosphorylation Comments:  induces phosphorylation at S36